Historic and Emerging Applications of BCG in Prevention and Treatment of Disease

Main Article Content

Denise Louise Faustman


Bacillus Calmette Guerin (BCG) was introduced 100 years ago for vaccination against tuberculosis and 40 years ago for treatment of bladder cancer.  Yet the last decade has witnessed a surge of new uses of BCG in the prevention or treatment of autoimmune disease, allergy and respiratory disease unrelated to tuberculosis.  This article reviews the efficacy and safety of the two main uses of BCG, tuberculosis prevention and bladder cancer treatment.  It discusses the animal and human studies underlying the new uses of BCG.  Finally, it covers the two avenues of basic science propelling the new uses of BCG, both of which rely on BCG role as an inducer of the cytokine Tumor Necrosis Factor (TNF):  the selective destruction of autoreactive T-lymphocytes and the induction of T-regulatory cells.

Article Details

How to Cite
FAUSTMAN, Denise Louise. Historic and Emerging Applications of BCG in Prevention and Treatment of Disease. Medical Research Archives, [S.l.], v. 2, n. 8, nov. 2015. ISSN 2375-1924. Available at: <https://www.journals.ke-i.org/index.php/mra/article/view/296>. Date accessed: 19 july 2018.
BCG vaccine, TNF
Research Articles


1. Gandhi NM, Morales A, & Lamm DL (2013) Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU international 112(3):288-297.

2. Colditz GA, et al. (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96(1 Pt 1):29-35.

3. Trunz BB, Fine P, & Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517):1173-1180.

4. paper Wp (2004) BCG vaccine. . Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 79(4):27-38.

5. Bohme J, et al. (1990) MHC-linked protection from diabetes dissociated from clonal deletion of T cells. Science 249(4966):293-295.

6. Rahman MM & McFadden G (2006) Modulation of tumor necrosis factor by microbial pathogens. PLoS pathogens 2(2):e4.

7. Luca S & Mihaescu T (2013) History of BCG Vaccine. Maedica 8(1):53-58.

8. Calmette A, Guerin C, & Negre L (1927) Sur la vaccination preventive des enfants nouveau-nes contre la tuberculose par le BCG. Ann Inst Pasteur, Lille 41:201-232.

9. Rodrigues LC, Diwan VK, & Wheeler JG (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. International journal of epidemiology 22(6):1154-1158.

10. Ritz N & Curtis N (2009) Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb) 89(4):248-251.

11. Liu J, et al. (2009) BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Human vaccines 5(2):70-78.

12. Milstien JB & Gibson JJ (1990) Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bulletin of the World Health Organization 68(1):93-108.

13. Aronson NE, et al. (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA : the journal of the American Medical Association 291(17):2086-2091.

14. Lotte A, et al. (1984) BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose 21:107-193.

15. Hesseling AC, et al. (2006) Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 42(4):548-558.

16. Casanova JL, et al. (1996) Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatrics 98(4 Pt 1):774-778.

17. Allard P, et al. (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. British journal of urology 81(5):692-698.

18. Kurth KH, et al. (1995) Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A(11):1840-1846.

19. Morales A, Eidinger D, & Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. The Journal of urology 116(2):180-183.

20. Lamm DL, et al. (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. The Journal of urology 124(1):38-40.

21. Pinsky CM, et al. (1985) Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer treatment reports 69(1):47-53.

22. Network NCC (2012) Bladder Cancer. in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). .
23. Shelley MD, et al. (2004) Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU international 93(4):485-490.

24. Han RF & Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216-1223.

25. Shang PF, et al. (2011) Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. The Cochrane database of systematic reviews (5):CD006885.

26. Lamm DL, et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology 163(4):1124-1129.

27. Sylvester RJ, van der MA, & Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. The Journal of urology 168(5):1964-1970.

28. Houghton BB, et al. (2013) Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU international 111(6):977-983.

29. Lamm DL, et al. (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. The Journal of urology 135(2):272-274.

30. Lamm DL, et al. (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. The Journal of urology 147(3):596-600.

31. Orihuela E, et al. (1987) Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60(3):326-333.

32. Koga H, et al. (2005) Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. International journal of urology : official journal of the Japanese Urological Association 12(2):145-151.

33. Ali-El-Dein B, et al. (2013) Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity. Urology annals 5(2):103-108.

34. Tinazzi E, et al. (2006) Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatology international 26(6):481-488.

35. Perez-Jacoiste Asin MA, et al. (2014) Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 93(17):236-254.

36. Singh B (2014) Prevention of type I diabetes and its recurrence by immunotherapy with mycobacterial adjuvants. The Value of BCG and TNF in Autoimmunity., (Academic Press, Boston, MA), p 2.

37. Strachan DP (1989) Hay-Fever, Hygiene, and Household Size. British Medical Journal 299(6710):1259-1260.

38. Sadelain MWJ, et al. (1990) Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39:583-589.

39. McInerney MF, Pek SB, & Thomas DW (1991) Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40:715-725.

40. Harada M, Kishimoto Y, & Makino S (1990) Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res. Clin. Prac. 8(2):85-89.

41. Shehadeh N, et al. (1994) Effect of adjuvant therapy on development of diabetes in mouse and man [see comments]. Lancet 343(8899):706-707.

42. Rabinovitch A, et al. (1995) Tumor necrosis factor mediates the protective effect of Freund's adjuvant against autoimmune diabetes in BB rats. J. Autoimmunity 8(3):357-366.

43. Ryu S, et al. (2001) Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. The Journal of clinical investigation 108(1):63-72.

44. Kodama S, et al. (2003) Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302:1223-1227.

45. Pozzilli P (1997) BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group. Lancet 349(9064):1520-1521.

46. Allen HF, et al. (1999) Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes care 22(10):1703-1707.

47. Dahlquist G & Gothefors L (1995) The cumulative incidence of childhood diabetes mellitus in Sweden unaffected by BCG-vaccination [letter] [see comments]. Diabetologia 38(7):873-874.

48. Parent ME, et al. (1997) Bacille Calmette-Guerin vaccination and incidence of IDDM in Montreal, Canada. Diabetes care 20(5):767-772.

49. Huppmann M, et al. (2005) Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes care 28(5):1204-1206.

50. Karaci M & Aydin M (2002) Effect of BCG vaccine in the prevention of type 1 diabetes mellitus. Contemp J Med 2:1-8.

51. Karaci M (2014) The Protective Effect of the BCG Vaccine on the Development of Type 1 Diabetes in Humans. The Value of BCG and TNF in Autoimmunity., (Academic Press, Waltham, Massachusetts), First Edition Ed, pp 52-62.

52. Shehadeh N, et al. (1997) Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice. Isr J Med Sci 33(11):711-715.

53. Faustman DL, et al. (2012) Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PloS one 7(8):e41756.

54. Ristori G, et al. (2014) Effects of the Bacillus Calmette-Guerin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System. The Value of BCG and TNF in Autoimmunity., (Academic Press, Boston, MA), pp 63-80.

55. Ristori G, et al. (1999) Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology 53(7):1588-1589.

56. Ristori G, et al. (2014) Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 82(1):41-48.

57. Tran SD, et al. (2007) Reversal of Sjogren's-like syndrome in non-obese diabetic mice. Ann Rheum Dis 66(6):812-814.

58. Faustman D, et al. (1991) Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science 254:1756-1761.

59. Krause S, et al. (2006) Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis 65(8):1021-1027.

60. Kodama S, Davis M, & Faustman DL (2005) The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci 62(16):1850-1862.

61. Naeslund C (1932) Resultats des experience de vaccination par le BCG poursuivies dans le Norrbotten (Suede) Septembre 1927-Decembre 1931. Vaccination Preventative de la Tuberculose de I Homme et des Animaux par le BCG: Rapports et Documents Provenant des Divers Pays (Ia France exceptee)), pp 274-281.

62. Aaby P & Benn CS (2012) Saving lives by training innate immunity with bacille Calmette-Guerin vaccine. Proceedings of the National Academy of Sciences of the United States of America 109(43):17317-17318.

63. Garly ML, et al. (2003) BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 21(21-22):2782-2790.

64. Roth A, et al. (2005) BCG vaccination scar associated with better childhood survival in Guinea-Bissau. International journal of epidemiology 34(3):540-547.

65. Roth A, et al. (2006) Tuberculin reaction, BCG scar, and lower female mortality. Epidemiology 17(5):562-568.

66. de Castro MJ, Pardo-Seco J, & Martinon-Torres F (2015) Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

67. Aaby P, et al. (2011) Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 204(2):245-252.

68. Biering-Sorensen S, et al. (2012) Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J 31(3):306-308.

69. Thostesen LM, et al. (2015) Bacillus Calmette-Guerin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial. Contemp Clin Trials 42:213-218.

70. Del Prete G (1992) Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 47(5):450-455.

71. Barlan IB, et al. (2005) Role of bacillus Calmette-Guerin as an immunomodulator for the prevention and treatment of allergy and asthma. Curr Opin Allergy Clin Immunol 5(6):552-557.

72. Herz U, et al. (1998) BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol 102(5):867-874.

73. Erb KJ, et al. (1998) Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. The Journal of experimental medicine 187(4):561-569.

74. Ke X, et al. (2010) Protective effects of combined Mycobacterium bovis BCG and interleukin-12 vaccination on airway inflammation in a murine model of allergic asthma. Clin Invest Med 33(3):E196-202.

75. Alm JS, et al. (1997) Early BCG vaccination and development of atopy. Lancet 350(9075):400-403.

76. El-Zein M, et al. (2010) Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. International journal of epidemiology 39(2):469-486.

77. Linehan MF, et al. (2014) Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. J Allergy Clin Immunol 133(3):688-695 e614.

78. Choi IS & Koh YI (2002) Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol 88(6):584-591.

79. Choi IS & Koh YI (2003) Effects of BCG revaccination on asthma. Allergy 58(11):1114-1116.

80. Li J, et al. (2005) Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study. Chin Med J (Engl) 118(19):1595-1603.

81. Vargas MH, et al. (2004) Effect of BCG vaccination in asthmatic schoolchildren. Pediatr Allergy Immunol 15(5):415-420.

82. Bohle A, et al. (1990) Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2(3):175-181.

83. Hieber U & Heim ME (1994) Tumor necrosis factor for the treatment of malignancies. Oncology 51(2):142-153.

84. Hayashi T & Faustman D (1999) NOD mice are defective in proteasome production and activation of NF- kappaB. Mol Cell Biol 19(12):8646-8659.

85. Ban L, et al. (2008) Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proceedings of the National Academy of Sciences of the United States of America 105(36):13644-13649.

86. Faustman DL & Davis M (In press) NF-kB,Autoimmunity and Mycobacteria. JSM Microbiology.

87. Lin L, DeMartino GN, & Greene WC (1998) Co-translational biogenesis of NF-kappa B p50 by the 26S proteasome. Cell 92:819-828.

88. Devergne O, et al. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16(12):7098-7108.

89. Miyara M, et al. (2011) Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmunity reviews 10(12):744-755.

90. Bennett CL, et al. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature genetics 27(1):20-21.

91. Wildin RS, et al. (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature genetics 27(1):18-20.

92. Olleros ML, et al. (2002) Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 168(7):3394-3401.

93. Olleros ML, et al. (2012) Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules. PloS one 7(5):e31469.

94. Garcia I, et al. (2011) Roles of soluble and membrane TNF and related ligands in mycobacterial infections: effects of selective and non-selective TNF inhibitors during infection. Advances in experimental medicine and biology 691:187-201.

95. Li Q, et al. (2006) Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Cancer immunology, immunotherapy : CII 55(12):1470-1479.

96. Grell M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83(5):793-802.

97. Chen X, et al. (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4(+)CD25(+) T regulatory cells. Journal of Immunology 179(1):154-161.

98. Chen X, et al. (2008) Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 180(10):6467-6471.

99. Okubo Y, et al. (2013) Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Scientific reports 3:3153.

100. Faustman DL & Davis M (2013) TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine. Frontiers in immunology 4:478.

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.